NextCure
NXTC
43 hedge funds and large institutions have $15.4M invested in NextCure in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
10% more funds holding
Funds holding: 39 → 43 (+4)
0.15% more ownership
Funds ownership: 3.86% → 4.01% (+0.15%)
8% less capital invested
Capital invested by funds: $16.6M → $15.4M (-$1.27M)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$195K |
| 2 |
AI
Acuitas Investments
Seattle,
Washington
|
+$104K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$82K |
| 4 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$70.4K |
| 5 |
Renaissance Technologies
New York
|
+$52.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$341K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$214K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$75.8K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$47.1K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$26K |
NXTC Hedge Fund Activity: Q4 2023 in Review
43 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q4 2023, worth a combined $15.4M — down 7.6% from $16.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NXTC positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 9 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $195K. The largest seller was Millennium Management, cutting an estimated $341K.
- 43 institutional investors held NextCure (NXTC) as of Q4 2023, up from 39 in Q3 2023.
- Funds reported $15.4M of NextCure stock for Q4 2023, down 7.6% quarter-over-quarter.
- 9 funds opened new NextCure positions in Q4 2023 and 5 closed out, a net change of +4 holders.
- The largest NextCure buyer in Q4 2023 was Morgan Stanley, an estimated $195K added.
- The largest NextCure seller in Q4 2023 was Millennium Management, an estimated $341K sold.
Based on aggregated 13F filings for Q4 2023.